Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
wharton's jelly-derived mesenchymal stem cell therapy
- Development stage
- Preclinical
- Lead developer
- BHI Biologics
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Intramuscular, Intraarticular
01
Overview
Wharton's jelly-derived mesenchymal stem cell therapy is a cell-based therapeutic developed by BHI Therapeutic Sciences (part of Blue Horizon International). The therapy utilizes mesenchymal stem cells (MSCs) isolated from Wharton's jelly, the gelatinous connective tissue found within the umbilical cord. These cells are characterized by high proliferation rates, multilineage differentiation potential, and low immunogenicity compared to adult-derived MSCs. The mechanism of action involves tissue repair and immunomodulation primarily through paracrine signaling, where the MSCs secrete bioactive molecules and factors that modulate the local microenvironment and promote regeneration. The therapy is being applied across a broad spectrum of indications, including autoimmune diseases, neurological disorders, cardiac conditions, and orthopedic injuries.
- Other names
- Mesenchymal stem cells (Wharton's Jelly)MSC (Wharton's Jelly)WJ-MSCsWharton's jelly-derived mesenchymal stem cells
Beyond the preview
Go deeper on wharton's jelly-derived mesenchymal stem cell therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on wharton's jelly-derived mesenchymal stem cell therapy.